FindTrial
Sign In

Interleukin-2 (IL-2)

DRUG11 trials

Sponsors

National Cancer Institute (NCI), French National Agency for Research on AIDS and Viral Hepatitis, University of Michigan Rogel Cancer Center, St. Jude Children's Research Hospital, Loma Linda University

Conditions

Acute Lymphoblastic LeukemiaAdvanced Ovarian CancerCMVChromophobe Renal Cell CarcinomaChronic Myelogenous LeukemiaHIV InfectionsImmunosuppressionJuvenile Myelomonocytic Leukemia

Early Phase 1

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
RecruitingNCT06318871
Dana-Farber Cancer InstituteChromophobe Renal Cell Carcinoma, Renal Carcinoma, Renal Cell Carcinoma +2
Start: 2024-08-28End: 2031-07-28Target: 10Updated: 2026-01-29

Phase 1

Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
CompletedNCT00697671
St. Jude Children's Research HospitalAcute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia +2
Start: 2007-03-31End: 2013-05-31Updated: 2013-07-16
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
CompletedNCT03158935
University Health Network, TorontoAdvanced Ovarian Cancer, Malignant Melanoma
Start: 2017-07-07End: 2020-08-04Updated: 2020-08-14
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
WithdrawnNCT06190249
James Isaacs, MDStage IIIB Melanoma, Stage IIIC Melanoma, Stage IIID Melanoma
Start: 2024-12-02End: 2028-07-31Updated: 2025-06-05
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
Not yet recruitingNCT07443020
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)Malignant Mesothelioma, Malignant Pleural Effusion, Metastasis to Pleura +1
Start: 2026-03-01End: 2038-03-01Target: 10Updated: 2026-03-02

Phase 2

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
CompletedNCT00059475
National Cancer Institute (NCI)Melanoma
Start: 2003-04-30End: 2010-05-31Updated: 2012-10-23
Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)
CompletedNCT00113282
French National Agency for Research on AIDS and Viral HepatitisHIV Infections
Start: 2004-06-30End: 2008-02-29Updated: 2011-12-22
Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine
TerminatedNCT00176761
University of Michigan Rogel Cancer CenterMetastatic Colorectal Cancer
Start: 2000-03-31End: 2006-05-31Target: 27Updated: 2006-09-11
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
WithdrawnNCT01355562
Loma Linda UniversityMelanoma, Metastatic Kidney Cancer
Start: 2011-03-31End: 2012-02-29Updated: 2020-04-30
Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer
Not yet recruitingNCT05810792
Sahlgrenska University HospitalImmunosuppression, Metastasis, Pancreatic Cancer +1
Start: 2024-04-01End: 2028-04-01Target: 50Updated: 2023-11-22
Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia
Not yet recruitingNCT06971913
Peking University People's HospitalCMV, SLE (Systemic Lupus)
Start: 2025-05-20End: 2025-12-30Target: 100Updated: 2025-05-14

Related Papers

A phase Ib study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel) with adjuvant pembrolizumab (PEMBRO) for treatment of immunotherapy naïve patients with high-risk clinical stage IIIb-d resectable melanoma (MEL).
Journal of Clinical Oncology2025-05-281 citations
Natural Killer Cell-Based Immunotherapy against Solid Cancer
OALib2021-01-011 citations
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
Cancer Immunology Immunotherapy2019-02-11132 citations
A phase Ib trial of pembrolizumab (Pembro) following adoptive cell therapy (ACT) in patients with platinum-resistant ovarian cancer; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) trial.
Journal of Clinical Oncology2018-05-201 citations